Synthesis, characterization, and biological activity of a triphenylphosphonium-containing imidazolium salt against
Michael L Stromyer1, Marie R Southerland1, Uttam Satyal2
1Department of Chemistry, The University of Akron, 190 East Buchtel Commons, Akron, OH, 44325, USA.
Abstract:
Imidazolium salts have shown great promise as anticancer materials. A new imidazolium salt (TPP1), with a triphenylphosphonium substituent, has been synthesized and evaluated for in vitro and in vivo cytotoxicity against bladder cancer. TPP1 was determined to have a GI50 ranging from 200 to 250 μM over a period of 1 h and the ability to effectively inhibit bladder cancer. TPP1 induces apoptosis, and it appears to act as a direct mitochondrial toxin. TPP1 was applied intravesically to a bladder cancer mouse model based on the carcinogen N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN). Cancer selectivity of TPP1 was demonstrated, as BBN-induced tumors exhibited apoptosis but normal adjacent urothelium did not. These results suggest that TPP1 may be a promising intravesical agent for the treatment of bladder cancer.
Insights
A novel imidazolium salt, TPP1, shows significant promise as an intravesical treatment for bladder cancer. This compound effectively inhibits cancer cell growth by inducing apoptosis and acting as a mitochondrial toxin, with demonstrated selectivity for tumors over healthy tissue.
Area of Science:
- Medicinal Chemistry
- Oncology
- Pharmacology
Background:
- Imidazolium salts are recognized for their potential as anticancer agents.
- Bladder cancer remains a significant health concern requiring novel therapeutic strategies.
Purpose of the Study:
- To synthesize and evaluate a new imidazolium salt, TPP1, for its efficacy against bladder cancer.
- To investigate the in vitro and in vivo mechanisms of action and selectivity of TPP1.
Main Methods:
- Synthesis of the triphenylphosphonium-substituted imidazolium salt (TPP1).
- In vitro cytotoxicity assays to determine the half-maximal growth inhibitory concentration (GI50).
- In vivo intravesical administration of TPP1 in a N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)-induced bladder cancer mouse model.
- Assessment of apoptosis induction and tissue selectivity.
Main Results:
- TPP1 exhibited a GI50 between 200-250 μM, indicating effective inhibition of bladder cancer cells.
- Intravesical TPP1 application in a mouse model induced apoptosis specifically in BBN-induced tumors.
- Normal urothelial tissues adjacent to tumors did not undergo apoptosis, demonstrating cancer selectivity.
Conclusions:
- TPP1 demonstrates significant in vitro and in vivo anticancer activity against bladder cancer.
- The compound acts as a direct mitochondrial toxin and induces apoptosis selectively in tumor cells.
- TPP1 represents a promising candidate for development as an intravesical agent for bladder cancer treatment.
